Next Article in Journal
Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3
Next Article in Special Issue
Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?
Previous Article in Journal
Propranolol Promotes Glucose Dependence and Synergizes with Dichloroacetate for Anti-Cancer Activity in HNSCC
Previous Article in Special Issue
Back to the Future? The Fallopian Tube, Precursor Escape and a Dualistic Model of High-Grade Serous Carcinogenesis
Open AccessReview

Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer

Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada
Cancers 2018, 10(12), 477; https://doi.org/10.3390/cancers10120477
Received: 24 October 2018 / Revised: 19 November 2018 / Accepted: 29 November 2018 / Published: 30 November 2018
(This article belongs to the Special Issue BRCA Mutations and Cancer)
Women with BRCA mutations, who choose to decline or defer risk-reducing mastectomy, require a highly sensitive breast screening regimen they can begin by age 25 or 30. Meta-analysis of multiple observational studies, in which both mammography and magnetic resonance imaging (MRI) were performed annually, demonstrated a combined sensitivity of 94% for MRI plus mammography compared to 39% for mammography alone. There was negligible benefit from adding screening ultrasound or clinical breast examination to the other two modalities. The great majority of cancers detected were non-invasive or stage I. While the addition of MRI to mammography lowered the specificity from 95% to 77%, the specificity improved significantly after the first round of screening. The median follow-up of women with screen-detected breast cancer in the above observational studies now exceeds 10 years, and the long-term breast cancer-free survival in most of these studies is 90% to 95%. However, ongoing follow-up of these study patients, as well of women screened and treated more recently, is necessary. Advances in imaging technology will make highly sensitive screening accessible to a greater number of high-risk women. View Full-Text
Keywords: breast cancer; screening; mammography; magnetic resonance imaging (MRI); sensitivity; specificity; survival; BRCA1; BRCA2 breast cancer; screening; mammography; magnetic resonance imaging (MRI); sensitivity; specificity; survival; BRCA1; BRCA2
MDPI and ACS Style

Warner, E. Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer. Cancers 2018, 10, 477.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop